From: Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors
Demographics | |||||||
---|---|---|---|---|---|---|---|
Patient # | Sex | Age | Primary Location | Stage | FDG Time PI | FMISO Time PI | HPV |
1 | M | 79 | Oropharynx | T3N2c | 91 | 171 | – |
2 | M | 67 | Oropharynx | T3N1 | 82 | 193 | – |
3 | M | 48 | Oropharynx | T1N1 | 65 | 181 | – |
4 | M | 54 | Larynx | T2N2bM0 | 74 | 157 | – |
5 | M | 62 | Oropharynx | T4N2c | 131 | 147 | – |
6 | M | 60 | Oropharynx | T2N1 | 83 | 153 | – |
7 | M | 64 | Oropharynx | T2N2b | 71 | 166 | – |
8 | M | 60 | Oropharynx | T4N2c | 50 | 180 | – |
9 | M | 62 | Oropharynx | T4aN2c | 69 | 196 | – |
10 | M | 55 | Oropharynx | T2N1 | 85 | 115 | – |
11 | M | 66 | Oropharynx | T1N3 | 180 | 155 | – |
12 | M | 56 | Oropharynx | T3N2c | 85 | 157 | – |
13 | M | 47 | Oropharynx | T3N1 | 68 | 153 | – |
14 | M | 57 | Oropharynx | T2N2c | 75 | 160 | HPV+ |
15 | M | 25 | Oropharynx | T2N2bM0 | 85 | 156 | HPV+ |
16 | M | 56 | Oropharynx | T2N2bM0 | 63 | 154 | HPV+ |
17 | F | 63 | Oropharynx | T2N2bM1 | 80 | 182 | HPV+ |
18 | M | 57 | Oropharynx | T1N2b | 66 | 148 | HPV+ |
19 | M | 49 | Oropharynx | T2N2b | 68 | 135 | HPV− |
20 | M | 58 | Oropharynx | T2N2b | 77 | 181 | HPV+ |